| Recruiting | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma NCT06898970 | Varun Monga, MBBS | Phase 2 |
| Recruiting | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986 | Fudan University | Phase 2 |
| Not Yet Recruiting | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897 | ECOG-ACRIN Cancer Research Group | N/A |
| Recruiting | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Soli NCT06440005 | Angiex, Inc. | Phase 1 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars NCT06375941 | Italian Sarcoma Group | — |
| Recruiting | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation The NCT06239272 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Withdrawn | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma NCT05799612 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154 | HRYZ Biotech Co. | Phase 2 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Recruiting | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients NCT07432932 | Royal Marsden NHS Foundation Trust | — |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Recruiting | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients NCT05961761 | Niels Junker | Phase 2 |
| Withdrawn | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma NCT04607200 | Agenus Inc. | Phase 2 |
| Recruiting | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sar NCT04055220 | Centre Leon Berard | N/A |
| Completed | Propranolol in Angiosarcoma NCT04518124 | The Netherlands Cancer Institute | Phase 2 |
| Completed | Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma NCT04293289 | Cancer Intelligence Care Systems, Inc. | N/A |
| Active Not Recruiting | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer NCT03860272 | Agenus Inc. | Phase 1 |
| Active Not Recruiting | Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) NCT03331250 | Massachusetts General Hospital | Phase 2 |
| Completed | A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embo NCT02625389 | Guerbet | Phase 4 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Effi NCT02732678 | Assistance Publique Hopitaux De Marseille | Phase 1 / Phase 2 |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Terminated | Evaluation of Votrient in Angiosarcoma NCT02212015 | Heidelberg University | Phase 2 |
| Unknown | Identification, Molecular Epidemiology Angiosarcoma of the Liver France NCT01786889 | Centre Oscar Lambret | N/A |
| Completed | Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angio NCT01303497 | Centre Oscar Lambret | Phase 2 |
| Recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379 | QuantumLeap Healthcare Collaborative | Phase 2 |
| Completed | Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes NCT00887809 | Memorial Sloan Kettering Cancer Center | Phase 2 |